This company develops and provides 4D human tissue models based on organ-on-a-chip technology for in vitro testing. Their platform simulates in vivo-like conditions, including blood flow, to support safety, efficacy, and permeation studies for product claims. They enable clients to obtain reliable claim support data efficiently and ethically without animal experimentation.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional in vitro testing methods for chemicals, cosmetic formulations, and pharmaceuticals often rely on static models that do not accurately replicate in vivo conditions, leading to inefficiencies and a high failure rate in clinical trials. Furthermore, the reliance on animal testing presents ethical concerns and regulatory challenges.
Solution
REVIVO BioSystems provides advanced 4D human tissue models and automated organ-on-a-chip platforms designed for in vitro safety, efficacy, and mechanistic testing. Their technology simulates in vivo conditions, including blood flow, to offer more accurate and efficient assessments of ingredients and formulations. This approach enables cruelty-free claim support and provides deeper insights into product performance, facilitating stronger commercial propositions and smoother regulatory navigation. The platform aims to reduce the failure rate of preclinical studies and accelerate the development of new products across various industries.
Target Audience
Primary customers include pharmaceutical companies, cosmetic and personal care manufacturers, contract research organizations (CROs), and academic research institutions seeking to improve the accuracy and ethical standards of their in vitro testing protocols.
Features
- 4D human tissue models that mimic in vivo conditions, including simulated blood flow.
- Organ-on-a-chip microfluidic platform for dynamic testing of chemicals, cosmetic formulations, and pharmaceuticals.
- Automated fraction collector (ReleGO™) and microfluidic chip (REV ex™) for streamlined sample collection and analysis.
- Enables assessment of permeability, safety, efficacy, and mechanism of action for ingredients and formulations.
- Supports long-term tissue viability and high-throughput screening capabilities.
- Reduces man-hours for in vitro testing by up to 20 times compared to traditional methods.
- Patented technology with applications for skin, and potential expansion to other barrier tissues like the gut and lungs.
- Facilitates personalized testing by enabling the use of patient-derived cells.